In this older patient with T2DM, HFpEF, and other comorbidities, which class of medication is most appropriate--and guideline-recommended?
Payal Kohli, MD
The new "sweet spot" in diabetes management is the interdisciplinary approach that is essential to treating all aspects of the disease. New diabetes medications also hit that spot.
Daily aspirin for primary prevention of heart disease is a practice under scrutiny. Based on the new 2019 ACC/AHA CVD prevention guidelines, is this patient a candidate?
Evidence-based revisions to the AHA/ACC/HRS guidelines will affect management of your patients with atrial fibrillation. Do you know how? Find out with a quick quiz.
Andexxa, CABANA, and new AF score. Cardiologist and Patient Care author Payal Kohli, MD, highlights 3 pivotal developments from 2018.
From "Danger of sepsis" to "Birthday today," the EHR covers it all. Will a popup on prescribing anticoagulation catch on?
Use of opioids in therapeutic doses in a large population of young veterans was linked to new-onset atrial fibrillation in a study reported at the AHA Scientific Sessions 2018.
A 20-year observational study of nearly 7000 elite athletes found only 0.3% developed atrial fibrillation. Is it time to think differently?
A new study reveals the notable impact of the variation in published stroke rates on the net clinical benefit of anticoagulation in atrial fibrillation.
The popular CHA2DS2-Vasc stroke risk calculator has its detractors. But will a newly proposed scoring system have a significant clinical impact?